There are currently 45 active clinical trials seeking participants for Systemic Lupus Erythematosus research studies. The states with the highest number of trials for Autism participants are California, Florida, Texas and New York.
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
NCT05440422
Recruiting
Background: People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke. No medications have been effective at reducing this risk in people with lupus. Objective: To test whether a drug (anifrolumab) can improve blood vessel function and reduce blood vessel inflammation in people with SLE. Eligibility: People aged 18 to 80 years with SLE. Design: Participants will undergo screening. Th... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/09/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Systemic Lupus Erythematosus, Cardiovascular Disease, Premature Atherosclerosis
Register for Updates
FT819 in Moderate to Severe Active Systemic Lupus Erythematosus
NCT06308978
Recruiting
This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following conditioning chemotherapy in participants with moderate to severe active systemic lupus erythematosus (SLE). The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT819.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/06/2024
Locations: University of Minnesota Medical School, Minneapolis, Minnesota +1 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
NCT05162586
Recruiting
The purpose of this Proof of Concept (PoC) and Dose-finding (DF) basket study is to evaluate the efficacy and safety of orally administered Enpatoran over 24 weeks in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE; subacute cutaneous lupus erythematosus [SCLE] and/or discoid lupus erythematosus [DLE]) participants in a randomized, double-blind, placebo-controlled, parallel, adaptive and dose-ranging setting. Study Duration: 33 weeks Visit Frequency: every 2 or 4 weeks... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/05/2024
Locations: The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California +175 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)
NCT02633163
Recruiting
The purpose of this study is to evaluate the efficacy and safety of mesenchymal stem cells (MSCs) obtained from umbilical cords for the treatment of adults with systemic lupus erythematosus (SLE). The goal of this study is to determine if patients receiving an MSC infusion plus standard of care respond better than patients receiving placebo infusion plus standard of care.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/29/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California +8 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
NCT00775476
Recruiting
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease which often has debilitating and potentially life-threatening consequences. The cause of SLE is unknown and current therapies lack specificity and carry significant side-effects. We previously discovered the depletion of glutathione in lymphocytes of patients with SLE and associated this metabolic change with the elevation of the mitochondrial transmembrane potential. This study will titrate to tolerance during an initial 3 mo... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/27/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California +4 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
NCT05540327
Recruiting
The purpose of the study is to evaluate the long term safety and efficacy of orally administered M5049 in participants with subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE) and/or systemic lupus erythematosus (SLE) who have completed the 24 week treatment period of Willow study (MS200569_0003 [NCT05162586]).
Gender:
All
Ages:
Between 18 years and 76 years
Trial Updated:
02/19/2024
Locations: Advance Medical Research Center, Miami, Florida +66 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Safety of the Herpes Zoster Subunit Vaccine in Lupus
NCT05559671
Recruiting
This randomized, double-blind, placebo-controlled, non-inferiority crossover study will evaluate the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate safety and immunogenicity in patients with variable baseline clinical activities, ages and immunosuppressant exposures. The investigators hypothesize that HZ/su administration will be non-inferior to placebo with respect to the risk of moderate or severe SLE flare(s) occurring within 24 weeks of receiving the first dose of... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
02/16/2024
Locations: NYU Langone Health, New York, New York +1 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Centrally Acting ACE Inhibition in SLE
NCT04486118
Recruiting
SLE is a chronic autoimmune disease that often involves multiple systems and organs of the body. An autoimmune disease is one which your immune system attacks the cells and tissues in different parts of the body. SLE is characterized by inflammation that leads to tissue damage in many different organ systems. Lupus can cause fever, joint pains, rashes, and other symptoms. It can also affect organs such as the skin, the muscles, the kidneys, the heart, the lungs, the blood and the brain. The exac... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
02/09/2024
Locations: Yale University School of Medicine, New Haven, Connecticut +6 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
NCT03276923
Recruiting
This multi-site registry, centered at Duke University, will enroll pregnant women with autoimmune and rheumatologic diseases. The main goal of MADRA is to identify ways to improve the health of women with rheumatic diseases and their babies during pregnancy. Prior studies demonstrate the importance of increase inflammation prior to and during pregnancy on these outcomes. The future research will seek to better define these risk factors and to identify ways to may improve them.
Gender:
Female
Ages:
All
Trial Updated:
01/25/2024
Locations: Duke University, Durham, North Carolina
Conditions: Autoimmune Diseases, Pregnancy Related, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma
Register for Updates
Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus
NCT05306873
Recruiting
The primary purpose of this study is to evaluate the potential effectiveness of 24 weeks of MMF within previously discovered immunologically defined subsets of SLE patients. Treatment effects will be evaluated within the individual immunologically-homogenous subsets defined at screening. This study will also explore and compare pre-randomization gene expression patterns among responders and non-responders to MMF and MMF plus voclosporin, use comprehensive immunophenotyping to study the immunolog... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
01/18/2024
Locations: UCLA Medical Center: Division of Rheumatology, Los Angeles, California +10 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Rheumatology Patient Registry and Biorepository
NCT04402086
Recruiting
To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
12/21/2023
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
Register for Updates
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
NCT05029336
Recruiting
A subset of autoimmune diseases (ADs) in children and young adults are life-threatening and unresponsive to conventional treatments. In these patients, the delivery of high dose immunosuppressive therapy followed by autologous stem cell transplant (ASCT) offers a treatment strategy capable of purging the pathogenic, autoreactive immune system and an opportunity for "immune reset." This strategy has been used in adults across a myriad of indications with evidence for efficacy. This study proposes... Read More
Gender:
All
Ages:
Between 8 years and 25 years
Trial Updated:
11/27/2023
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Systemic Lupus Erythematosus, Systemic Sclerosis
Register for Updates